Health economic models in hemophilia A and utility assumptions from a clinician's perspective.
Pediatr Blood Cancer
; 62(10): 1826-31, 2015 Oct.
Article
em En
| MEDLINE
| ID: mdl-25976056
ABSTRACT
BACKGROUND:
The clinical benefits of prophylaxis in patients with hemophilia are well-established and include the following reduced bleeding episodes, prevention of joint damage, decreased inhibitor development, and improved health-related quality of life. However, the cost-effectiveness of prophylaxis is still not clear. PROCEDURES We reviewed the published hemophilia prophylaxis economic models focusing on utility assumptions.RESULTS:
We found six cost-utility studies that compared prophylaxis and on-demand regimens. These studies reported remarkably different results, using utility values based on different assumptions and data sources.CONCLUSIONS:
We suggest that cooperation among key stakeholders (clinicians, patient organizations and health-care decision makers) as a means of collecting evidence-based and experiential data to represent both the utility and the quality of life changes for patients with Hemophilia A who are treated with prophylaxis or receive on-demand treatments may represent a winning strategy with which to resolve the outstanding issues related to health technology assessments in the care of patients with hemophilia.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Garantia da Qualidade dos Cuidados de Saúde
/
Análise Custo-Benefício
/
Modelos Econômicos
/
Hemofilia A
Tipo de estudo:
Etiology_studies
/
Health_economic_evaluation
/
Health_technology_assessment
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Pediatr Blood Cancer
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Itália